EUCTR2008-000562-23-DE进行中（未招募）不适用
Randomised, Double-Blind, Cross-over Study to Assess the Efficacyand Safety of 4 Weeks of Once Daily Treatment of 2 Doses of OrallyInhaled BI 1744 CL, each in fixed dose combination (FDC) with 5µgTiotropium Bromide (Delivered by the Respimat® Inhaler) in Patientswith COPD - Efficacy and Safety of 4 Weeks QD orally inhaled FDC BI 1744/tiotropium via RESPIMAT in COPD
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent, diagnosis of COPD, post-bronchodilator FEV1 of more or equal 30% of predicted normal and less than 80% of predicted normal, 40 years of age or older, current or ex-smokers with a smoking history of more than 10 pack-years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Significant disease other than COPD, abnormal baseline laboratory, history of asthma or total blood eosinophil count of equal or more than 600 per mm3, history of myocardial infarction/life-threatening pulmonary obstruction/cystic fibrosis/bronchiectasis/alcohol or drug abuse, treatment with medications which prolong the QT/QTc interval, treatment with oral ß-adrenergics/ß-blockers/oral corticosteroids at unstable doses or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day, use of daytime oxygen for more than one hour per day, currently undergoing rehabilitation (or within prior 6 weeks), other investigational drug, known hypersensitivity to ß-adrenergics or anticholinergics or other components of the drug product
研究者
相似试验
进行中（未招募）
不适用
Randomised, Double-Blind, Cross-over Study to Assess the Efficacyand Safety of 4 Weeks of Once Daily Treatment of 2 Doses of OrallyInhaled BI 1744 CL, each in fixed dose combination (FDC) with 5µgTiotropium Bromide (Delivered by the Respimat® Inhaler) in Patientswith COPD - Efficacy and Safety of 4 Weeks QD orally inhaled FDC BI 1744/tiotropium via RESPIMAT in COPDEUCTR2008-000562-23-BESCS Boehringer Ingelheim Comm.V126
进行中（未招募）
1 期
Functional MRI study of the central effects of erenumab in patients with episodic migraine.Episodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-004875-11-ITOVARTIS FARMA S.P.A.140
进行中（未招募）
1 期
Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 mcg [2 actuations of 2,5 mg], 10 mcg [2 actuations of 5 mcg]) or Twice Daily (2 mcg [2 actuations of 1 mcg], 5 mg [2 actuations of 2,5 mcg]) Administration in Patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-006334-10-NLBoehringer Ingelheim BV48
进行中（未招募）
1 期
A Randomized, Double-Blind, Cross-Over Study Comparing the Pharmacodynamic Response in Subjects with Acute Coronary Syndrome Receiving 14 Days 10-mg Maintenance Dose Prasugrel (LY640315) versus 14 Days 150-mg Maintenance Dose Clopidogrel After Using a 900-mg Loading Dose of Clopidogrel to Reduce Ongoing Platelet Activation – The ACAPULCO Study - ACAPULCO StudyEUCTR2006-002618-37-FREli Lilly and Company70
进行中（未招募）
1 期
Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations of 2.5 mg], 10 mg [2 actuations of 5 mg]) or Twice Daily (2 µg [2 actuations of 1 mg], 5 mg [2 actuations of 2.5 mg]) Administration in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2008-006334-10-BESCS Boehringer Ingelheim Comm.V48